AstraZeneca vaccine as third dose effective against Omicron: Study
PTI, Jan 13, 2022, 4:00 PM IST
Image for representation
London: The AstraZeneca Vaxzevaria vaccine showed an increased antibody response to the Omicron variant of COVID-19 after a third booster dose, preliminary data released by the Anglo-Swedish biopharma major said on Thursday.
In an ongoing safety and immunogenicity trial of the vaccine, a formulation developed by Oxford University and administered in India as Covishield, it was found that given as a third dose increased the body’s immune response to Beta, Delta, Alpha and Gamma SARS-CoV-2 variants.
A separate analysis of samples from the trial showed increased antibody response to the Omicron variant. The results were observed among individuals previously vaccinated with either Vaxzevria or an mRNA vaccine.
The company said it is submitting this additional data to health authorities around the world given the urgent need for third dose boosters.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Top News
Related Articles More
Exposure to outdoor artificial light at night may increase risk of stroke, study finds
Group of oncologists launch free-of-cost second opinion helpline number for cancer patients
Dogs understand more than they let on, create mental images of known words: Study
Caution advised as diarrhoea cases rise with onset of summer
Bharat Biotech begins clinical trials of TB vaccine on adults in India
MUST WATCH
Latest Additions
Congress’s Kolar conundrum remains unsolved despite CM, DCM attempt to quell dissent
Mangaluru: Illegal slaughterhouse raided by police, Three arrested
‘No evidence of wrongdoing’: CBI closes UPA-era Air India aircraft leasing
NIA arrests key conspirator in Bengaluru’s Rameshwaram Cafe blast case: Officials
RCB batting coach McKenzie backs Maxwell to come out of lean run